• R Bonometti, M C Sacchi, P Stobbione, E C Lauritano, S Tamiazzo, A Marchegiani, E Novara, E Molinaro, I Benedetti, L Massone, A Bellora, and R Boverio.
• Department of Emergency Medicine, Santi Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy. ramona.bonometti@gmail.com.
• Eur Rev Med Pharmacol Sci. 2020 Sep 1; 24 (18): 9695-9697.

AbstractCoronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, SARS-CoV-2. The acute phase may be followed by a second phase actually not yet completely understood but probably associated to an autoimmune activation. At the moment is not possible to clearly define an association between immunological findings and pathological symptoms, however, this case report describes the case of a patient who following COVID-19 infection development autoimmune antibodies who persist in time longer than viral phase. Those antibodies can be responsible for the multi pathological clinical picture showed from our patient that, according to EULAR 2019 criteria, could be classified as systemic lupus erythematosus (SLE). SLE is probably one of the possible chronic rheumatologic diseases triggers by COVID-19 and this is the first case of SLE with vasculitis actually described in literature.

16 keywords...

hide…